Table 2.

Meta-Analysis of XPC Gene Polymorphisms and Prostate Cancer Association

				Sample size			Test of association			Test of heterogeneity
Polymorphism		Comparsion	Number of studies	Case	Control	Model	OR (95% CI)	Z	p-Value	χ2	p-Value	I2 (%)
rs2228001	Overall	C vs. A	3932	3940	5	F	1.05 (0.95–1.15)	0.94	0.35	6.68	0.15	40.1
		AC+CC vs. AA	1966	1970	5	F	1.02 (0.90–1.16)	0.33	0.74	1.49	0.83	0.0
		CC vs. AA+AC	1966	1970	5	R	1.16 (0.73–1.84)	0.62	0.53	13.61	0.009	70.6
		CC vs. AA	1074	1058	5	R	1.14 (0.72–1.82)	0.57	0.57	12.16	0.02	67.1
		AC vs. AA	1676	1710	5	F	0.99 (0.86–1.13)	0.18	0.86	0.50	0.97	0.0
	Asian	C vs. A	1124	1272	3	R	1.08 (0.80–1.45)	0.51	0.61	5.87	0.05	65.9
		AC+CC vs. AA	562	636	3	F	1.06 (0.84–1.33)	0.48	0.63	0.92	0.63	0.0
		CC vs. AA+AC	562	636	3	R	1.20 (0.46–3.11)	0.36	0.72	12.56	0.002	84.1
		CC vs. AA	326	362	3	R	1.20 (0.47–3.07)	0.38	0.71	11.11	0.004	82.0
		AC vs. AA	493	575	3	F	1.00 (0.78–1.27)	0.04	0.97	0.10	0.95	0.0
	Gleason	AC+CC vs. AA	224	136	2	F	0.85 (0.55–1.31)	0.74	0.46	0.50	0.48	0.0
	Pt	AC+CC vs. AA	172	195	2	F	1.18 (0.77–1.80)	0.77	0.44	0.17	0.68	0.0
PAT+/−	Overall	+vs. −	794	942	2	F	1.39 (1.12–1.71)	3.06	0.002	0.63	0.43	0.0
		+/−and+/+vs.−/−	397	471	2	F	1.30 (1.00–1.70)	1.93	0.05	1.35	0.25	25.8
		+/+vs.−/−and+/−	397	471	2	F	2.07 (1.33–3.23)	3.21	0.001	0.12	0.73	0.0
		+/+vs.−/−	252	298	2	F	2.20 (1.39–3.48)	3.35	0.0008	0.00	0.99	0.0
		+/−vs.−/−	340	436	2	F	1.12 (0.84–1.50)	0.80	0.42	1.71	0.19	41.4
	Bone metastasis	+vs. −	304	442	2	R	1.34 (0.71–2.52)	0.90	0.37	4.15	0.04	75.9
		+/−and+/+vs.−/−	152	221	2	F	1.27 (0.84–1.92)	1.12	0.26	1.98	0.16	49.4
		+/+vs.−/−and+/−	152	221	2	R	1.70 (0.57–5.04)	0.95	0.34	3.29	0.07	69.6
		+/+vs.−/−	95	136	2	R	1.79 (0.52–6.14)	0.92	0.36	3.79	0.05	73.6
		+/−vs.−/−	123	193	2	F	1.11 (0.70–1.75)	0.45	0.65	0.54	0.46	0.0

R, random effect model; F, fixed effect model; OR, odds ratio; CI, confidence interval.